Nxera Pharma Co (TSE:4565) Cyclically Adjusted FCF per Share: 円10.06 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4565 Nxera Pharma Co Ltd TSE:4565
73 GF Score
Price 円912.00
GF Value 円1,348.94
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Nxera Pharma Co Cyclically Adjusted FCF per Share?

Nxera Pharma Co TSE:4565 +0.33% 73 Cyclically Adjusted FCF per Share is 円10.06 as of Mar. 2026. GuruFocus rates TSE:4565 with a GF Score™ of 73/100 and a GF Value™ of 円1,348.94 (Possible Value Trap). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Nxera Pharma Co's adjusted free cash flow per share for the three months ended in Mar. 2026 was 円-77.573. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is 円10.06 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Nxera Pharma Co's average Cyclically Adjusted FCF Growth Rate was -65.90% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -29.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Nxera Pharma Co was 26.50% per year. The lowest was -29.00% per year. And the median was 7.60% per year.

As of today (2026-07-22), Nxera Pharma Co's current stock price is 円912.00. Nxera Pharma Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was 円10.06. Nxera Pharma Co's Cyclically Adjusted Price-to-FCF of today is 90.66.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Nxera Pharma Co was 145.53. The lowest was 24.55. And the median was 55.04.


Nxera Pharma Co  (TSE:4565) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Nxera Pharma Co's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=912.00/10.06
=90.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Nxera Pharma Co was 145.53. The lowest was 24.55. And the median was 55.04.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Nxera Pharma Co Cyclically Adjusted FCF per Share Related Terms


Nxera Pharma Co Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Nxera Pharma Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nxera Pharma Co Cyclically Adjusted FCF per Share Chart

Nxera Pharma Co Annual Data
Trend Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.00 46.26 37.38 28.37 16.59

Nxera Pharma Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.53 27.06 22.81 16.59 10.06

TSE:4565 vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Nxera Pharma Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nxera Pharma Co Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's Cyclically Adjusted Price-to-FCF falls into.


TSE:4565
73GF Score
Nxera Pharma Co Ltd TSE:4565
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nxera Pharma Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nxera Pharma Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-77.573/112.7000*112.7000
=-77.573

Current CPI (Mar. 2026) = 112.7000.

Nxera Pharma Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 201.958 98.100 232.015
201609 -18.391 98.000 -21.150
201612 -6.697 98.400 -7.670
201703 8.558 98.100 9.832
201706 -4.228 98.500 -4.838
201709 -0.059 98.800 -0.067
201712 -4.127 99.400 -4.679
201803 -30.907 99.200 -35.113
201806 -30.136 99.200 -34.237
201809 -34.598 99.900 -39.031
201812 -15.976 99.700 -18.059
201903 2.978 99.700 3.366
201906 -4.869 99.800 -5.498
201909 52.960 100.100 59.626
201912 -10.444 100.500 -11.712
202003 17.703 100.300 19.892
202006 -5.428 99.900 -6.123
202009 14.106 99.900 15.913
202012 31.983 99.300 36.299
202103 -11.794 99.900 -13.305
202106 -7.301 99.500 -8.270
202109 -17.589 100.100 -19.803
202112 113.412 100.100 127.688
202203 -20.621 101.100 -22.987
202206 -20.582 101.800 -22.786
202209 96.956 103.100 105.984
202212 58.687 104.100 63.535
202303 -15.710 104.400 -16.959
202306 -23.197 105.200 -24.851
202309 -21.461 106.200 -22.775
202312 -13.922 106.800 -14.691
202403 -25.200 107.200 -26.493
202406 40.814 108.200 42.511
202409 16.324 108.900 16.894
202412 -135.125 110.700 -137.566
202503 3.903 111.100 3.959
202506 -2.998 111.700 -3.025
202509 -34.154 112.000 -34.367
202512 -3.246 113.000 -3.237
202603 -77.573 112.700 -77.573

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of 円10.06 mean?
Nxera Pharma Co (TSE:4565) has a Cyclically Adjusted FCF per Share of 円10.06 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Nxera Pharma Co and its competitors.
Is Nxera Pharma Co's Cyclically Adjusted FCF per Share too high?
Nxera Pharma Co's current Cyclically Adjusted FCF per Share is 円10.06. Overall, Nxera Pharma Co has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nxera Pharma Co's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Nxera Pharma Co's Cyclically Adjusted FCF per Share of 円10.06 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Nxera Pharma Co and its competitors. Nxera Pharma Co's current Cyclically Adjusted FCF per Share is 円10.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nxera Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Nxera Pharma Co (TSE:4565) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,348.94, compared to a current price of 円912.00 — trading 32.4% below its estimated fair value. The current Cyclically Adjusted FCF per Share is 円10.06. Nxera Pharma Co's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Nxera Pharma Co (TSE:4565), the current Cyclically Adjusted FCF per Share is 円10.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nxera Pharma Co (TSE:4565) Overvalued in 2026?

Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be undervalued. The current stock price of 円912.00 is trading 32.4% below its estimated GF Value™ of 円1,348.94. GuruFocus considers Nxera Pharma Co to be Possible Value Trap.

Key valuation signals for TSE:4565:

  • Cyclically Adjusted FCF per Share: 円10.06
  • GF Value™: 円1,348.94 vs. price of 円912.00 (32.4% below fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the TSE:4565 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nxera Pharma Co Business Description

Other Exchanges SOLTF:USA
Address Midtown East, 9-7-2 Akasaka Minato-ku, Tokyo, JPN, 107-0052
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
73GF Score

Get the complete analysis for TSE:4565

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円912.00
Price
円1,348.94
GF Value